NCT04606407

Inhaled NO for the Treatment of Viral Pneumonia in Adults

Completed NA Last updated 16 December 2022

What this trial tests

NA trial testing LungFit™ in Viral Pneumonia in 40 participants. Completed in 7 August 2022.

Timeline

25 November 2020

Primary endpoint
7 August 2022

7 August 2022

Quick facts

Lead sponsor	Beyond Air Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	25 November 2020
Primary completion	7 August 2022
Estimated completion	7 August 2022
Sites	3 locations across Israel

Drugs / interventions tested

• LungFit™

Conditions studied

• Viral Pneumonia — all drugs for Viral Pneumonia →
• Nitric Oxide — all drugs for Nitric Oxide →
• Respiratory Disease — all drugs for Respiratory Disease →
• Pneumonia, Viral — all drugs for Pneumonia, Viral →

Sponsor

Beyond Air Inc. — full company profile →

Who can join

Adults 18 to 80, any sex, with Viral Pneumonia or Nitric Oxide. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this multi center, open label, randomized, study is to obtain information on the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with viral pneumonia

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. Inhaled Nitric Oxide Delivery Systems for Mechanically Ventilated and Nonintubated Patients: A Review.
   Gianni S, Carroll RW, Kacmarek RM, Berra L. · · 2021 · cited 23× · PMID 34039761 · DOI 10.4187/respcare.08856
2. Nitric Oxide Signaling and Sensing in Age-Related Diseases.
   Mazuryk O, Gurgul I, Oszajca M, Polaczek J, et al · · 2024 · cited 14× · PMID 39456466 · DOI 10.3390/antiox13101213
3. Gasotransmitters in Modern Medicine: Promises and Challenges in the Use of Porous Crystalline Carriers.
   Pinto RV, Pinto ML, Serre C. · · 2025 · cited 7× · PMID 40059496 · DOI 10.1002/adhm.202404553
4. A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomised clinical study.
   Wolak T, Dicker D, Shifer Y, Grossman A, et al · · 2024 · cited 6× · PMID 39060420 · DOI 10.1038/s41598-024-68055-w
5. Utility of NO and H₂S donating platforms in managing COVID-19: Rationale and promise.
   Oza PP, Kashfi K. · · 2022 · cited 6× · PMID 36029975 · DOI 10.1016/j.niox.2022.08.003